June 10, 2021 06:26 AM EDT
People
Pharma

Cit­ing 'ex­ces­sive' ex­ec­u­tive com­pen­sa­tion, ad­vi­so­ry firms want a long­time Re­gen­eron board mem­ber oust­ed

Max Gelman

Senior Editor

Grum­bles have grown loud­er at Re­gen­eron in re­cent months over the pay pack­ages re­ceived by top ex­ecs, and now two large ad­vi­so­ry firms are rec­om­mend­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times